Docket No. S-20359D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GOFF et al.

APPLICATION NO: TBA

FILED: Concurrently herewith

Art Unit: TBD

FOR: CONTROL OF GENE EXPRESSION IN PLANTS BY RECEPTOR MEDIATED TRANSACTIVATION IN THE PRESENCE OF A CHEMICAL LIGAND

Commissioner of Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION

Sir:

The sequence listing of the present application is identical to the sequence listing in parent application no. 09/625,904, filed July 26, 2000.

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the CRF that will be used for the present application. Pursuant to 37 C.F.R. § 1.821(f), Applicants' attorney hereby certifies that the contents of the CRF submitted in parent application no. 09/625,904, filed July 26, 2000, and the paper form sequence listing submitted in the present application are the same. Pursuant to 37 CFR §1.821(e) please use the computer readable form (CRF) in parent application serial no. 09/625,904 for the present application.

Respectfully submitted,

J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

Syngenta
Patent Department
P.O. Box 12257
Research Triangle Park, NC 27709-2257
(919) 541-8587
Date: March 21, 2001

Docket No. S-20359D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GOFF et al.

APPLICATION NO: TBA

FILED: Concurrently herewith

FOR: CONTROL OF GENE EXPRESSION IN PLANTS BY RECEPTOR MEDIATED TRANSACTIVATION IN THE PRESENCE OF A CHEMICAL LIGAND

Art Unit: TBD

Commissioner of Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION

Sir:

The sequence listing of the present application is identical to the sequence listing in parent application no. 09/625,904, filed July 26, 2000.

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the CRF that will be used for the present application. Pursuant to 37 C.F.R. § 1.821(f), Applicants' attorney hereby certifies that the contents of the CRF submitted in parent application no. 09/625,904, filed July 26, 2000, and the paper form sequence listing submitted in the present application are the same. Pursuant to 37 CFR §1.821(e) please use the computer readable form (CRF) in parent application serial no. 09/625,904 for the present application.

Respectfully submitted,



J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

Syngenta
Patent Department
P.O. Box 12257
Research Triangle Park, NC 27709-2257
(919) 541-8587
Date: March 21, 2001

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Goff, Stephen A
Crossland, Lyle D
Privalle, Laura S

(ii) TITLE OF INVENTION: Control of Gene Expression in Plants by Receptor Mediated Transactivation in the Presence of a Chemical Ligand

(iii) NUMBER OF SEQUENCES: 11

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: CIBA-GEIGY Corporation
(B) STREET: 7 Skyline Drive
(C) CITY: Hawthorne
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10532

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30B

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US TBA
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Spruill, W. Murray
(B) REGISTRATION NUMBER: 32,943
(C) REFERENCE/DOCKET NUMBER: CGC 1796

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 919-541-8590
(B) TELEFAX: 919-541-8689

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF43"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGCGGATCCT AAACAATGAA GCGGCGCTGG TCGAACAACG GC 42

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF23"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGCGGGATCC ATGCGGCCGG AATGCGTCGT CCCG 34

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF42"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGCGGATCCA TGGACAACTG CGACCAGGAC 30

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF37"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCGGGATCCC CCACCGTACT CGTCAATTC 29

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SA115"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTCGAGCTCT CGGATCCTAA AACAATGGCC CCCCCGACCG ATGTC 45

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF25"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GATCCGACAA GGGTTCAATG CACTTGTCA 29

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF26"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GATCTGACAA GTGCATTGAA CCCTTGTCG 29

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF30"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CGCGGATCCA TGGGTCGCGA TGATCTCTCG CCTTC 35

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..11
(D) OTHER INFORMATION: /note= "polylinker used to link the C1 transactivation domain to EcR"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

VGSRSRVSSH A 11

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "positive strand oligonucleotide used to create pSKGAL2.3"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGGGGATCC TAAGTAAGTA AGGTAC 26

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "complementary strand oligonucleotide used to create pSKGAL2.3"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTTACTTACT TAGGATCCCC 20